NeoImmune

Universal Medicine is a technology developer in the field of immune system, dedicated to the development of key technologies for high-throughput reading and writing of T and B lymphocyte receptor profiles and their applications in clinical testing and treatment, focusing on technology developers in the field of immune system . Recently announced the completion of a 30 million RMB Pre-A round of strategic financing. WinX Capital is acting as a financial advisor. This round of investment was initiated by Kangsheng Global. Ruijiang Kangsheng Fund managed by Ruijiang Investment led the investment. The investors included Spark Venture Capital and Yangtze River Source Fund. This round of funds will be mainly used for the promotion of hematological tumor MRD products and the research and development of new clinical products.

NeoImmune headquartered in Asia, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $56.4M in funding across 12 round(s). With a team of 11-50 employees, NeoImmune is actively contributing to advancements in Biotechnology. Their latest funding round, Seed Round - NeoImmune, raised $4.7M. Discover more about their projects, partnerships, and impact on our platform.